Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Works matching IS 11707690 AND DT 2006 AND VI 24 AND IP 12
Results: 10
1
2
The Authors' Reply.
- Published in:
- 2006
- By:
- Publication type:
- Letter
3
Discounting health effects in pharmacoeconomic evaluations: current controversies.
- Published in:
- 2006
- By:
- Publication type:
- commentary
4
Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension.
- Published in:
- 2006
- By:
- Publication type:
- journal article
5
Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia.
- Published in:
- 2006
- By:
- Publication type:
- journal article
6
Cost Effectiveness of Tumour Necrosis Factor-α Inhibitors as First-Line Agents in Rheumatoid Arthritis.
- Published in:
- PharmacoEconomics, 2006, v. 24, n. 12, p. 1221, doi. 10.2165/00019053-200624120-00006
- By:
- Publication type:
- Article
7
Generic health-related quality-of-life assessment in children and adolescents: methodological considerations.
- Published in:
- 2006
- By:
- Publication type:
- journal article
8
Assessing Generalisability in Model-Based Economic Evaluation Studies: A Structured Review in Osteoporosis.
- Published in:
- PharmacoEconomics, 2006, v. 24, n. 12, p. 1181, doi. 10.2165/00019053-200624120-00004
- By:
- Publication type:
- Article
9
Letter from the commissioner's office at the US FDA.
- Published in:
- 2006
- By:
- Publication type:
- Editorial
10
Do pharmacogenomic tests provide value to policy makers?
- Published in:
- 2006
- By:
- Publication type:
- Editorial